← Insider buys

JAZZ

Jazz Pharmaceuticals plc · Healthcare

Insiders sold $63.4M of Jazz Pharmaceuticals plc in the last 12 months and bought none

$0Bought, 12 mo
$63.4MSold, 12 mo
$13.9BMarket cap

JAZZ over the last year

No insider buys filed in this year

JAZZ after insider buys

3 months after each buy, from the first price a copier could get.

2 buys have 3 months of prices so far. A record shows here at 3.

Congress

Members reported 2 trades in JAZZ since 2023.

Every filing

286 insider filings since 2016, newest first

JAZZSell

Renee D Gala · President and CEO

$473K−1.4%Oct 7
JAZZSell

Bruce C Cozadd · Director

$1.4M−1.7%Oct 5
JAZZSell

Neena M Patil · EVP and Chief Legal Officer

$289K−2.5%Sep 14
JAZZSell

Renee D Gala · President and CEO

$486K−1.4%Sep 10
JAZZSell

Bruce C Cozadd · Director

$1.5M−1.7%Sep 2
JAZZSell

Robert Iannone · EVP, Global Head of R&D & CMO

$19.2M−53.9%Aug 31
JAZZSell

Bruce C Cozadd · Director

$1.5M−1.6%Aug 5
JAZZSell

Bruce C Cozadd · Director

$1.4M−1.6%Jul 6
JAZZSell

Mark Douglas Smith · Director

$267K−10.7%Jun 17
JAZZSell

Neena M Patil · EVP and Chief Legal Officer

$278K−2.3%Jun 12
JAZZSell

Bruce C Cozadd · Director

$1.4M−1.6%Jun 3
JAZZSell

Neena M Patil · EVP and Chief Legal Officer

$282K−2.2%Jun 1
JAZZSell

Samantha Pearce · EVP and Chief Commercial Officer

$1.6M−12.1%Jun 1
JAZZSell

Rick E Winningham · Director

$662K−22.3%May 27
JAZZSell

Heather Ann Mcsharry · Director

$482K−9.8%May 27
JAZZSell

Bruce C Cozadd · Director

$1.2M−2.0%May 5
JAZZSell

Bruce C Cozadd · Director

$1.1M−2.0%Apr 3
JAZZSell

Patricia Carr · SVP and Chief Accounting Officer

$235K−17.0%Mar 9
JAZZSell

Bruce C Cozadd · Director

$1.1M−1.0%Mar 4
JAZZSell

Norbert G Riedel · Director

$656K−16.0%Mar 2
JAZZSell

Patricia Carr · SVP and Chief Accounting Officer

$456K−20.0%Mar 2
JAZZSell

Neena M Patil · EVP and General Counsel

$10.7M−49.0%Mar 2
JAZZSell

Mary Elizabeth Henderson · SVP, Technical Operations

$1.0M−16.0%Mar 2
JAZZSell

Mary Elizabeth Henderson · SVP, Technical Operations

$379K−10.0%Dec 11
JAZZSell

Patricia Carr · SVP and Chief Accounting Officer

$798K−40.0%Dec 9
JAZZSell

Bruce C Cozadd · Director

$13.8M−16.0%Dec 1
JAZZSell

Heather Ann Mcsharry · Director

$607K−14.0%Nov 24
JAZZBuy

Seamus Mulligan · Director

$10.0M+9.0%May 13
JAZZSell

Neena M Patil · EVP and General Counsel

$457K−10.0%Nov 13
JAZZSell

Bruce C Cozadd · Chair and CEO

$111KNov 5
JAZZSell

Mary Elizabeth Henderson · SVP, Technical Operations

$153K−9.0%Sep 11
JAZZSell

Neena M Patil · EVP and General Counsel

$548K−12.0%May 7
JAZZSell

Patricia Carr · SVP and Chief Accounting Officer

$438K−36.0%Mar 8
JAZZBuy

Philip L Johnson · EVP and CFO

$1.4M+75.0%Mar 5
JAZZSell

Mark Douglas Smith · Director

$50K−6.0%Dec 6
JAZZSell

Jennifer E. Cook · Director

$50K−6.0%Dec 6
JAZZSell

Neena M Patil · EVP and General Counsel

$216K−5.0%Sep 6
JAZZSell

Neena M Patil · EVP and General Counsel

$105K−2.0%Aug 17
JAZZSell

Rick E Winningham · Director

$171K−11.0%Aug 15
JAZZSell

Catherine A. Sohn · Director

$171K−8.0%Aug 15
JAZZSell

Anne Oriordan · Director

$171K−9.0%Aug 15
JAZZSell

Kenneth W O'Keefe · Director

$171K−4.0%Aug 15
JAZZSell

Mark Douglas Smith · Director

$171K−15.0%Aug 15
JAZZSell

Norbert G Riedel · Director

$171K−8.0%Aug 15
JAZZSell

Heather Ann Mcsharry · Director

$186K−7.0%Aug 15
JAZZSell

Peter Gray · Director

$171K−7.0%Aug 15
JAZZSell

Patrick G Enright · Director

$171K−6.0%Aug 15
JAZZSell

Jennifer E. Cook · Director

$171K−15.0%Aug 15
JAZZSell

Neena M Patil · EVP and General Counsel

$205K−5.0%Jun 5
JAZZSell

Renee D Gala · EVP and CFO

$790K−14.0%May 19
About Jazz Pharmaceuticals plc

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products in the United States, Europe, and internationally. The company offers Xywav to treat cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia (IH); Epidiolex for seizures associated with Lennox-Gastaut syndrome (LGS), Dravet syndrome (DS), or tuberous sclerosis complex (TSC); Rylaze for the treatment of acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Zepzelca for the treatment of metastatic small cell lung cancer with disease progression on or after platinum-based chemotherapy; Ziihera to treat HER2-positive biliary tract cancers; Modeyso for the treatment of diffuse midline glioma harboring an H3 K27M mutation; and Defitelio to treat severe veno-occlusive disease. It also develops Zanidatamab in Phase 3 trial to treat HER2-positive gastroesophageal adenocarcinoma (GEA) and biliary tract cancers (BTC); Dordaviprone to treat H3 K27M-mutant diffuse glioma; and Vyxeos for the treatment of newly-diagnosed therapy-related acute myeloid leukemia. In addition, the company is developing Zanidatamab to treat neoadjuvant and adjuvant breast cancer; Vyxeos for the treatment of High-risk MDS, newly diagnosed untreated patients with high-risk AML, and De novo intermediate or adverse risk AML stratified by genomics; and JZP3507 to treat pheochromocytoma and paraganglioma that are in Phase 2 clinical trials. Further, it develops JZP815 to treat Raf and Ras mutant tumors; JZP898 for the IFN INDUKIN molecule in solid tumors; and JZP047 to treat absence epilepsy that are in Phase 1 clinical trials. The company collaboration agreements with Redx Pharma plc, Autifony Therapeutics Limited, Zymeworks Inc., Sumitomo Pharma Co., Ltd., Werewolf Therapeutics, Inc; and AbCellera Biologics Inc. Jazz Pharmaceuticals plc was founded in 2003 and is headquartered in Dublin, Ireland.

Filings come from SEC EDGAR and prices from daily closes. Not investment advice.